drugset
drugset / Trial / NCT06920498

A Study to Learn How Different Amounts of the Study Medicine Called PF-07941944 Are Tolerated in the Body of Healthy Adults.

NCT06920498 ↗

Phase 1 Completed 25 enrolled Pfizer
RandomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this clinical trial is to learn about the safety and tolerability of the study medicine (called PF-07941944) in healthy participants. This study is seeking participants who: * Are male or female between the ages of 18 and 60 * Are generally healthy The investigators will compare the experiences of people receiving the study medicine to those of the people who do not. This will help the investigators determine if the study medicine is safe and well tolerated. Participants enrolled in Part 1 will take part in this study for approximately 4 months. Participants enrolled in Part 2 or Part 3 will take part in this study for approximately 2.5 months. Study visits will take place at the study clinic. The study team will also call participants once at the end of the study over the phone.

Timeline

Start
2024-12-03
Primary completion
2025-06-19
Completion
2025-06-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Midazolam Small molecule — Oral
Subject PF-07941944 Unknown — Oral

Indications

No indication recorded.